Search

Your search keyword '"Arnol, M."' showing total 166 results
Start Over Author "Arnol, M."
166 results on '"Arnol, M."'

1. Recovery of dialysis patients with COVID-19: health outcomes 3 months after diagnosis in ERACODA

Author

Hemmelder, M. H., Noordzij, M., Vart, P., Hilbrands, L. B., Jager, K. J., Abrahams, A. C., Arroyo, D., Battaglia, Y., Ekart, R., Mallamaci, F., Malloney, S. -R., Oliveira, J., Rydzewski, A., Sridharan, S., Vogt, L., Duivenvoorden, R., Gansevoort, R. T., Franssen, C. F. M., van der Net, J. B., Essig, M., du Buf-Vereijken, P. W. G., van Ginneken, B., Maas, N., van Jaarsveld, B. C., Bemelman, F. J., Klingenberg-Salahova, F., Heenan-Vos, F., Vervloet, M. G., Nurmohamed, A., Abramowicz, D., Verhofstede, S., Maoujoud, O., Malfait, T., Fialova, J., Melilli, E., Fava, A., Cruzado, J. M., Perez, N. M., Lips, J., Krepel, H., Adilovic, H., Hengst, M., Konings, C. J. A. M., Braconnier, P., Weis, D., Gellert, R., Alferes, D. G., Radulescu, D., Zakharova, E. V., Ambuehl, P. M., Guidotti, R., Walker, A., Lepeytre, F., Rabate, C., Rostoker, G., Marques, S., Azasevac, T., Majstorovic, G. S., Katicic, D., Dam, M. T., Kruger, T., Brzosko, S., Liakopoulos, V., Zanen, A. L., Logtenberg, S. J. J., Fricke, L., Kuryata, O., Slebe, J. J. P., Abd ElHafeez, S., Kemlin, D., van de Wetering, J., Reinders, M. E. J., Hesselink, D. A., van Gestel, J. K., Eiselt, J., Kielberger, L., El-Wakil, H. S., Verhoeven, M. A. M., Logan, I., Canal, C., Facundo, C., Ramos, A. M., Debska-Slizien, A., Veldhuizen, N. M. H., Tigka, E., Polyzou Konsta, M. A., Panagoutsos, S., Postorino, A., Cambareri, F., Matceac, I., Nistor, I., Covic, A., Groeneveld, J. H. M., Jousma, J., Diekmann, F., Oppenheimer, F., Blasco, M., Pereira, T. A., dos Santos Junior, A. C. S., Arias-Cabrales, C., Crespo, M., Llinas-Mallol, L., Buxeda, A., Tarrega, C. B., Redondo-Pachon, D., Arenas Jimenez, M. D., Mendoza-Valderrey, A., Martins, A. C., Mateus, C., Alvila, G., Laranjinha, I., Hofstra, J. M., Siezenga, M. A., Franco, A., Castellano, S., Rodriguez-Ferrero, M. L., Manzanos, S. B., Haridian Sosa Barrios, R., Lemahieu, W., Bartelet, K., Dirim, A. B., Demir, E., Sever, M. S., Turkmen, A., Safak, S., Hollander, D. A. M. J., Kerckhoffs, A., Buttner, S., de Vries, A. P. J., Meziyerh, S., van der Helm, D., Mallat, M., Bouwsma, H., Petruliene, K., Verberk, I., van der Sande, F. M., Christiaans, M. H. L., Mohankumar, N., Luca, M. D., Tuglular, S. Z., Kramer, A., Beerenhout, C., Luik, P. T., Kerschbaum, J., Tiefenthaler, M., Watschinger, B., Adema, A. Y., Stepanov, V. A., Zulkarnaev, A. B., Turkmen, K., Gandolfini, I., Maggiore, U., Fliedner, A., Asberg, A., Mjoen, G., Miyasato, H., de Fijter, C. W. H., Mongera, N., Pini, S., de Biase, C., van de Logt, A. E., Maas, R., Lebedeva, O., Lopez, V., Reichert, L. J. M., Verhave, J., Titov, D., Parshina, E. V., Zanoli, L., Marcantoni, C., van Kempen, G., van Gils-Verrij, L. E. A., Harty, J. C., Meurs, M., Myslak, M., Lentini, P., den Deurwaarder, E., Stendahl, M., Rahimzadeh, H., Schouten, M., Rychlik, I., Cabezas-Reina, C. J., Roca, A. M., Nauta, F., Sahin, I., Goffin, E., Kanaan, N., Labriola, L., Devresse, A., Diaz-Mareque, A., Coca, A., de Arriba, G., Meijers, B. K. I., Naesens, M., Kuypers, D., Desschans, B., Tonnerlier, A., Wissing, K. M., Dedinska, I., Pessolano, G., Malik, S., Dounousi, E., Papachristou, E., Berger, S. P., Meijer, E., Sanders, J. S. F., Ozyilmaz, A., Ponikvar, J. B., Pernat, A. M., Kovac, D., Arnol, M., Molenaar, F. M., van Zuilen, A. D., Meijvis, S. C. A., Dolmans, H., Tantisattamo, E., Esposito, P., Krzesinski, J. -M., Barahira, J. D., Gallieni, M., Martin-Moreno, P. L., Guglielmetti, G., Guzzo, G., Toapanta, N., Soler, M. J., Luik, A. J., van Kuijk, W. H. M., Stikkelbroeck, L. W. H., Hermans, M. M. H., Rimsevicius, L., Righetti, M., Islam, M., Heitink-Ter Braak, N., Nephrology, ACS - Microcirculation, ACS - Diabetes & metabolism, UCL - SSS/IREC/NEFR - Pôle de Néphrologie, UCL - (SLuc) Service de néphrologie, Clinical sciences, Faculteit Medische Wetenschappen/UMCG, Groningen Kidney Center (GKC), Cardiovascular Centre (CVC), Groningen Institute for Organ Transplantation (GIOT), Interne Geneeskunde, RS: Carim - V02 Hypertension and target organ damage, Medical Informatics, APH - Aging & Later Life, APH - Quality of Care, APH - Global Health, ACS - Pulmonary hypertension & thrombosis, APH - Health Behaviors & Chronic Diseases, and Internal Medicine

Subjects
Male, Outcome Assessment, survival, mental health status, COVID-19 Testing, SDG 3 - Good Health and Well-being, Renal Dialysis, functional health status, Outcome Assessment, Health Care, 80 and over, Humans, KIDNEY-TRANSPLANT, AcademicSubjects/MED00340, Aged, Aged, 80 and over, Transplantation, SARS-CoV-2, MORTALITY, COVID-19, Middle Aged, Health Care, Intensive Care Units, Renal disorders Radboud Institute for Molecular Life Sciences [Radboudumc 11], Nephrology, dialysis, Original Article, Female, Renal disorders Radboud Institute for Health Sciences [Radboudumc 11]
Abstract

Background Coronavirus disease 2019 (COVID-19)-related short-term mortality is high in dialysis patients, but longer-term outcomes are largely unknown. We therefore assessed patient recovery in a large cohort of dialysis patients 3 months after their COVID-19 diagnosis. Methods We analyzed data on dialysis patients diagnosed with COVID-19 from 1 February 2020 to 31 March 2021 from the European Renal Association COVID-19 Database (ERACODA). The outcomes studied were patient survival, residence and functional and mental health status (estimated by their treating physician) 3 months after COVID-19 diagnosis. Complete follow-up data were available for 854 surviving patients. Patient characteristics associated with recovery were analyzed using logistic regression. Results In 2449 hemodialysis patients (mean ± SD age 67.5 ± 14.4 years, 62% male), survival probabilities at 3 months after COVID-19 diagnosis were 90% for nonhospitalized patients (n = 1087), 73% for patients admitted to the hospital but not to an intensive care unit (ICU) (n = 1165) and 40% for those admitted to an ICU (n = 197). Patient survival hardly decreased between 28 days and 3 months after COVID-19 diagnosis. At 3 months, 87% functioned at their pre-existent functional and 94% at their pre-existent mental level. Only few of the surviving patients were still admitted to the hospital (0.8–6.3%) or a nursing home (∼5%). A higher age and frailty score at presentation and ICU admission were associated with worse functional outcome. Conclusions Mortality between 28 days and 3 months after COVID-19 diagnosis was low and the majority of patients who survived COVID-19 recovered to their pre-existent functional and mental health level at 3 months after diagnosis.

Published
2022

2. COVID-19 Pandemic Waves and Mortality Among Patients on Kidney Replacement Therapy

Author

Vart, P., Jager, K.J., Arnol, M., Duivenvoorden, R., Franssen, C.F., Groeneveld, Marc, Hemmelder, M.H., Lepeytre, F., Malfait, T., Midtvedt, K., Mitra, S., Facundo, C., Noordzij, M., Reina, C.C., Safak, S., Toapanta, N., Hilbrands, L.B., Gansevoort, R.T., Vart, P., Jager, K.J., Arnol, M., Duivenvoorden, R., Franssen, C.F., Groeneveld, Marc, Hemmelder, M.H., Lepeytre, F., Malfait, T., Midtvedt, K., Mitra, S., Facundo, C., Noordzij, M., Reina, C.C., Safak, S., Toapanta, N., Hilbrands, L.B., and Gansevoort, R.T.

Abstract

Contains fulltext : 282615.pdf (Publisher’s version ) (Open Access)

Published
2022

4. Clinical triage of patients on kidney replacement therapy presenting with COVID-19: An ERACODA registry analysis

Author

Mitra, S., Jayanti, A., Vart, P., Coca, A., Gallieni, M., Ovrehus, M. A., Midtvedt, K., Abd Elhafeez, S., Gandolfini, I., Buttner, S., Franssen, C. F. M., Hemmelder, M. H., Van Der Net, J. B., Essig, M., Du Buf-Vereijken, P. W. G., Van Ginneken, B., Maas, N., Vogt, L., Van Jaarsveld, B. C., Jager, K. J., Bemelman, F. J., Klingenberg-Salahova, F., Heenan-Vos, F., Vervloet, M. G., Nurmohamed, A., Abramowicz, D., Verhofstede, S., Maoujoud, O., Malfait, T., Fialova, J., Melilli, E., Fava, A., Cruzado, J. M., Perez, N. M., Lips, J., Krepel, H., Adilovic, H., Hengst, M., Rydzewski, A., Gellert, R., Oliveira, J., Alferes, D. G., Zakharova, E. V., Ambuehl, P. M., Walker, A., Winzeler, R., Lepeytre, F., Rabate, C., Rostoker, G., Marques, S., Azasevac, T., Katicic, D., Dam, M. T., Kruger, T., Brzosko, S., Zanen, A. L., Logtenberg, S. J. J., Fricke, L., Slebe, J. J. P., Kemlin, D., Van De Wetering, J., Reinders, M. E. J., Eiselt, J., Kielberger, L., El-Wakil, H. S., Verhoeven, M. A. M., Canal, C., Facundo, C., Ramos, A. M., Debska-Slizien, A., Veldhuizen, N. M. H., Tigka, E., Konsta, M. A. P., Panagoutsos, S., Mallamaci, F., Postorino, A., Cambareri, F., Covic, A., Matceac, I., Nistor, I., Cordos, M., Groeneveld, J. H. M., Jousma, J., Marjolijn Van Buren, Diekmann, F., Tiago Assis Pereira, Santos, A. C. S., Arias-Cabrales, C., Crespo, M., Llinas-Mallol, L., Buxeda, A., Tarrega, C. B., Redondo-Pachon, D., Jimenez, M. D. A., Hofstra, J. M., Franco, A., Arroyo, D., Rodriguez-Ferrero, M. L., Manzanos, S. B., Barrios, R. H. S., Avila, G., Laranjinha, I., Mateus, C., Lemahieu, W., Bartelet, K., Dirim, A. B., Sever, M. S., Demir, E., Safak, S., Turkmen, A., Hollander, D. A. M. J., De Vries, A. P. J., Meziyerh, S., Van Der Helm, D., Mallat, M., Bouwsma, H., Sridharan, S., Petruliene, K., Maloney, S. -R., Verberk, I., Van Der Sande, F. M., Christiaans, M. H. L., Mohankumar, N., Di Luca, M., Tuglular, S. Z., Kramer, A., Beerenhout, C., Luik, P. T., Kerschbaum, J., Tiefenthaler, M., Watschinger, B., Adema, A. Y., Stepanov, V. A., Zulkarnaev, A. B., Turkmen, K., Fliedner, A., Asberg, A., Mjoen, G., Miyasato, H., De Fijter, C. W. H., Mongera, N., Pini, S., De Biase, C., Duivenvoorden, R., Hilbrands, L., Kerckhoffs, A., Van De Logt, A. -E., Maas, R., Lebedeva, O., Lopez, V., Verhave, J., Reichert, L. J. M., Titov, D., Parshina, E. V., Zanoli, L., Marcantoni, C., Van Gils-Verrij, L. E. A., Harty, J. C., Meurs, M., Myslak, M., Battaglia, Y., Lentini, P., Den Deurwaarder, E., Stendahl, M., Rahimzadeh, H., Schouten, M., Rychlik, I., Cabezas-Reina, C. J., Roca, A. M., Nauta, F., Goffin, E., Kanaan, N., Labriola, L., Devresse, A., Diaz-Mareque, A., Meijers, B. K. I., Naesens, M., Kuypers, D., Desschans, B., Tonnelier, A., Wissing, K. M., De Arriba, G., Dedinska, I., Pessolano, G., Maggiore, U., Malik, S., Papachristou, E., Gansevoort, R. T., Noordzij, M., Berger, S. P., Meijer, E., Ozyilmaz, A., Sanders, J. S. F., Ponikvar, J. B., Arnol, M., Pernat, A. M., Kovac, D., Ekart, R., Abrahams, A. C., Molenaar, F. M., Van Zuilen, A. D., Meijvis, S. C. A., Dolmans, H., Tantisattamo, E., Esposito, P., Krzesinski, J. -M., Barahira, J. D., Sabiu, G., Martin-Moreno, P. L., Guglielmetti, G., Guzzo, G., Toapanta, N., Soler, M. J., Luik, A. J., Van Kuijk, W. H. M., Stikkelbroeck, L. W. H., Hermans, M. M. H., Rimsevicius, L., Righetti, M., Islam, M., Braak, N. H. -T., Nephrology, UCL - SSS/IREC/NEFR - Pôle de Néphrologie, UCL - (SLuc) Service de néphrologie, Interne Geneeskunde, RS: Carim - V02 Hypertension and target organ damage, Groningen Kidney Center (GKC), ACS - Diabetes & metabolism, AII - Inflammatory diseases, AII - Infectious diseases, Internal Medicine, and Clinical sciences

Subjects
kidney, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), medicine.medical_treatment, Pulmonary insufficiency, infectious diseases, Kidney, Second presentation, Interquartile range, Internal medicine, medicine, Humans, Registries, Mortality, AcademicSubjects/MED00340, Dialysis, Aged, Transplantation, second presentation, business.industry, SARS-CoV-2, COVID-19, medicine.disease, mortality, Triage, Hospitalization, Renal Replacement Therapy, Renal disorders Radboud Institute for Molecular Life Sciences [Radboudumc 11], Nephrology, Oxygen Saturation, dialysis, Original Article, Hemodialysis, Renal disorders Radboud Institute for Health Sciences [Radboudumc 11], Presentation (obstetrics), business, transplantation
Abstract

Background Patients on kidney replacement therapy (KRT) are at very high risk of coronavirus disease 2019 (COVID-19). The triage pathway for KRT patients presenting to hospitals with varying severity of COVID-19 illness remains ill-defined. We studied the clinical characteristics of patients at initial and subsequent hospital presentations and the impact on patient outcomes. Methods The European Renal Association COVID-19 Database (ERACODA) was analysed for clinical and laboratory features of 1423 KRT patients with COVID-19 either hospitalized or non-hospitalized at initial triage and those re-presenting a second time. Predictors of outcomes (hospitalization, 28-day mortality) were then determined for all those not hospitalized at initial triage. Results Among 1423 KRT patients with COVID-19 [haemodialysis (HD), n = 1017; transplant, n = 406), 25% (n = 355) were not hospitalized at first presentation due to mild illness (30% HD, 13% transplant). Of the non-hospitalized patients, only 10% (n = 36) re-presented a second time, with a 5-day median interval between the two presentations (interquartile range 2–7 days). Patients who re-presented had worsening respiratory symptoms, a decrease in oxygen saturation (97% versus 90%) and an increase in C-reactive protein (26 versus 73 mg/L) and were older (72 vs 63 years) compared with those who did not return a second time. The 28-day mortality between early admission (at first presentation) and deferred admission (at second presentation) was not significantly different (29% versus 25%; P = 0.6). Older age, prior smoking history, higher clinical frailty score and self-reported shortness of breath at first presentation were identified as risk predictors of mortality when re-presenting after discharge at initial triage. Conclusions This study provides evidence that KRT patients with COVID-19 and mild illness can be managed effectively with supported outpatient care and with vigilance of respiratory symptoms, especially in those with risk factors for poor outcomes. Our findings support a risk-stratified clinical approach to admissions and discharges of KRT patients presenting with COVID-19 to aid clinical triage and optimize resource utilization during the ongoing pandemic.

Published
2021

5. COVID-19-related mortality in kidney transplant and haemodialysis patients: a comparative, prospective registry-based study

Author

Goffin, E., Candellier, A., Vart, P., Noordzij, M., Arnol, M., Covic, A., Lentini, P., Malik, S., Reichert, L. J. M., Duivenvoorden, R., Hilbrands, L.B., Maas, R.J.H., Sever, M.S., Watschinger, B., Jager, K.J., Gansevoort, R.T., Goffin, E., Candellier, A., Vart, P., Noordzij, M., Arnol, M., Covic, A., Lentini, P., Malik, S., Reichert, L. J. M., Duivenvoorden, R., Hilbrands, L.B., Maas, R.J.H., Sever, M.S., Watschinger, B., Jager, K.J., and Gansevoort, R.T.

Abstract

Item does not contain fulltext, BACKGROUND: Coronavirus disease 2019 (COVID-19) has exposed haemodialysis (HD) patients and kidney transplant (KT) recipients to an unprecedented life-threatening infectious disease, raising concerns about kidney replacement therapy (KRT) strategy during the pandemic. This study investigated the association of the type of KRT with COVID-19 severity, adjusting for differences in individual characteristics. METHODS: Data on KT recipients and HD patients diagnosed with COVID-19 between 1 February 2020 and 1 December 2020 were retrieved from the European Renal Association COVID-19 Database. Cox regression models adjusted for age, sex, frailty and comorbidities were used to estimate hazard ratios (HRs) for 28-day mortality risk in all patients and in the subsets that were tested because of symptoms. RESULTS: A total of 1670 patients (496 functional KT and 1174 HD) were included; 16.9% of KT and 23.9% of HD patients died within 28 days of presentation. The unadjusted 28-day mortality risk was 33% lower in KT recipients compared with HD patients {HR 0.67 [95% confidence interval (CI) 0.52-0.85]}. In a fully adjusted model, the risk was 78% higher in KT recipients [HR 1.78 (95% CI 1.22-2.61)] compared with HD patients. This association was similar in patients tested because of symptoms [fully adjusted model HR 2.00 (95% CI 1.31-3.06)]. This risk was dramatically increased during the first post-transplant year. Results were similar for other endpoints (e.g. hospitalization, intensive care unit admission and mortality >28 days) and across subgroups. CONCLUSIONS: KT recipients had a greater risk of a more severe course of COVID-19 compared with HD patients, therefore they require specific infection mitigation strategies.

Published
2021

13. Left Ventricular Mass Is Associated With Ventricular Repolarization Heterogeneity One Year After Renal Transplantation: In a study of 68 renal transplant recipients, greater left ventricular mass was associated with increased ventricular repolarization heterogeneity assessed by the beat-to-beat QT interval variability algorithm, providing a link with the high risk of arrhythmia and cardiac death in this population.

Author

Arnol, M., Starc, V., Knap, B., Potočnik, N., Bren, A. F., and Kandus, A.

Published
2008

17. Current preventive strategies and management of Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplantation in Europe. Results of the ESGICH Questionnaire-based Cross-sectional Survey

Author

San-Juan, R., Manuel, O., Hirsch, H. H., Fernandez-Ruiz, M., Lopez-Medrano, F., Comoli, P., Caillard, S., Grossi, P., Aguado, J. M., Alamo-Martinez, J. M., Anaya, F., Anttila, V. -J., Arnol, M., Avolio, Alfonso Wolfango, Baccarani, U., Castello, I. B., Boletis, I., Bonofiglio, R., Bressollette, C., Brockmann, J., Pulido, J. C., Catalan, P., Christiansen, C., Cofan, F., Cordero, E., Leiro, M. C., Dantal, J., D'Armini, A., Delgado, J. F., Strologo, L. D., Raimondo, F. D., Dierickx, D., Eis-Hubinger, A., Kremer, S. F., Faggian, G., Farinas, M. C., Folgueira, M. D., Fontana, I., Franco, A., Furian, L., Garzoni, C., Ghirardo, G., Ginevri, F., Grinyo, J., Gupte, G., Hansson, L., Helantera, I., Herrero, J. I., Hobin, D., Hoffmann, D., Jan, L., Jarque, I., Jespersen, B., Kaczmarek, I., Kevin, P., Koneth, I., Kovac, D., Lacaille, F., Lautenschlager, I., Len, O., Llado, L., Loy, M., Marcos Maeso, M. A., Marianne, L. V., Marsh, J., Meylan, P., Minambres, E., Montejo, M., Mueller, N., Munoz, P., Nadalin, S., Kamar, N., Nicolas, B., Olivier, D., Palomo, J., Pascual, M., Peter, J., Pierre, F., Francisca Portero, M., Provot, F., Boluda, E. R., Regalia, E., Reina, G., Reuter, S., Ricart, J., Garcia, M. R., Rollag, H., Russo, F. P., Sabe, N., Salcedo, M., Santambrogio, L., Seeman, T., Serra, N., Sgarabotto, D., Simonek, J., Thierry, Y., Thomsen, M. K., Tihic, N., Torre-Cisneros, J., Travi, G., Tulissi, P., Moal, V., Veroux, M., Santandreu, A. V., Vizzini, G., Zibar, L., Avolio A. W. (ORCID:0000-0003-2491-7625), San-Juan, R., Manuel, O., Hirsch, H. H., Fernandez-Ruiz, M., Lopez-Medrano, F., Comoli, P., Caillard, S., Grossi, P., Aguado, J. M., Alamo-Martinez, J. M., Anaya, F., Anttila, V. -J., Arnol, M., Avolio, Alfonso Wolfango, Baccarani, U., Castello, I. B., Boletis, I., Bonofiglio, R., Bressollette, C., Brockmann, J., Pulido, J. C., Catalan, P., Christiansen, C., Cofan, F., Cordero, E., Leiro, M. C., Dantal, J., D'Armini, A., Delgado, J. F., Strologo, L. D., Raimondo, F. D., Dierickx, D., Eis-Hubinger, A., Kremer, S. F., Faggian, G., Farinas, M. C., Folgueira, M. D., Fontana, I., Franco, A., Furian, L., Garzoni, C., Ghirardo, G., Ginevri, F., Grinyo, J., Gupte, G., Hansson, L., Helantera, I., Herrero, J. I., Hobin, D., Hoffmann, D., Jan, L., Jarque, I., Jespersen, B., Kaczmarek, I., Kevin, P., Koneth, I., Kovac, D., Lacaille, F., Lautenschlager, I., Len, O., Llado, L., Loy, M., Marcos Maeso, M. A., Marianne, L. V., Marsh, J., Meylan, P., Minambres, E., Montejo, M., Mueller, N., Munoz, P., Nadalin, S., Kamar, N., Nicolas, B., Olivier, D., Palomo, J., Pascual, M., Peter, J., Pierre, F., Francisca Portero, M., Provot, F., Boluda, E. R., Regalia, E., Reina, G., Reuter, S., Ricart, J., Garcia, M. R., Rollag, H., Russo, F. P., Sabe, N., Salcedo, M., Santambrogio, L., Seeman, T., Serra, N., Sgarabotto, D., Simonek, J., Thierry, Y., Thomsen, M. K., Tihic, N., Torre-Cisneros, J., Travi, G., Tulissi, P., Moal, V., Veroux, M., Santandreu, A. V., Vizzini, G., Zibar, L., and Avolio A. W. (ORCID:0000-0003-2491-7625)

Abstract

There is limited clinical evidence on the utility of the monitoring of Epstein-Barr virus (EBV) DNAemia in the pre-emptive management of post-transplant lymphoproliferative disease (PTLD) in solid organ transplant (SOT) recipients. We investigated current preventive measures against EBV-related PTLD through a web-based questionnaire sent to 669 SOT programmes in 35 European countries. This study was performed on behalf of the ESGICH study group from the European Society of Clinical Microbiology and Infectious Diseases. A total of 71 SOT programmes from 15 European countries participated in the study. EBV serostatus of the recipient is routinely obtained in 69/71 centres (97%) and 64 (90%) have access to EBV DNAemia assays. EBV monitoring is routinely used in 85.9% of the programmes and 77.4% reported performing pre-emptive treatment for patients with significant EBV DNAemia levels. Pre-emptive treatment for EBV DNAemia included reduction of immunosuppression in 50.9%, switch to mammalian target of rapamycin inhibitors in 30.9%, and use of rituximab in 14.5% of programmes. Imaging by whole-body 18-fluoro-deoxyglucose positron emission tomography (FDG-PET) is used in 60.9% of centres to rule out PTLD and complemented computer tomography is used in 50%. In 10.9% of centres, FDG-PET is included in the first-line diagnostic workup in patients with high-risk EBV DNAemia. Despite the lack of definitive evidence, EBV load measurements are frequently used in Europe to guide diagnostic workup and pre-emptive reduction of immunosuppression. We need prospective and controlled studies to define the impact of EBV monitoring in reducing the risk of PTLD in SOT recipients.

Published
2015

18. Current preventive strategies and management of Epstein–Barr virus-related post-transplant lymphoproliferative disease in solid organ transplantation in Europe. Results of the ESGICH Questionnaire-based Cross-sectional Survey

Author

San Juan, R, Manuel, O, Hirsch, Hh, Fernández Ruiz, M, López Medrano, F, Comoli, P, Caillard, S, Grossi, P, Aguado, Jm, Álamo Martínez JM, Anaya, F, Anttila, Vj, Arnol, M, Avolio, Aw, Baccarani, U, Castello, Ib, Boletis, I, Bonofiglio, R, Viamigliori, A, Bressollette, C, Brockmann, J, Pulido, Jc, Catalán, P, Christiansen, C, Cofan, F, Cordero, E, Leiro, Mc, Dantal, J, D'Armini, A, Delgado, Jf, Dello Strologo, L, Gesu, B, DI RAIMONDO, Francesco, Dierickx, D, Eis Hübinger, A, Kremer, Sf, Faggian, G, Fariñas, Mc, Folgueira, Md, Fontana, I, Franco, A, Furian, L, Garzoni, C, Ghirardo, G, Ginevri, F, Grinyó, J, Grossi, Pa, Gupte, G, Hansson, L, Helanterä, I, Herrero, Ji, Hobin, D, Hoffmann, D, Jan, L, Jarque, I, Jespersen, B, Kaczmarek, I, Klin, G, Kevin, P, Koneth, I, Kovac, D, Lacaille, F, Lautenschlager, I, Len, O, Lladó, L, Loy, M, Maeso, Ma, Marianne, Lv, Marsh, J, Meylan, P, Miñambres, E, Montejo, M, Mueller, N, Muñoz, P, Nadalin, S, Kamar, N, Nicolas, B, Olivier, D, Palomo, J, Pascual, M, Peter, J, Pierre, F, Portero, Mf, Provot, F, Boluda, Er, Regalia, E, Reina, G, Reuter, S, Ricart, Mj, García, Mr, Rollag, H, Russo, Fp, Sabé, N, Salcedo, M, Santambrogio, L, Seeman, T, Serra, N, Sgarabotto, D, Simonek, J, Thierry, Y, Thomsen, Mk, Tihic, N, Torre Cisneros, J, Travi, G, Tulissi, P, Moal, V, Veroux, Massimiliano, Santandreu, Av, Vizzini, G, Zibar, L., Clinicum, Department of Medicine, Infektiosairauksien yksikkö, Department of Virology, and Medicum

Subjects
Epstein-Barr Virus Infections, Cross-sectional study, Settore MED/18 - CHIRURGIA GENERALE, medicine.medical_treatment, Medizin, Epstein-Barr virus, Europe, Post-transplant lymphoproliferative disease, Pre-emptive treatment, Survey, Microbiology (medical), Infectious Diseases, medicine.disease_cause, Organ transplantation, Epstein–Barr virus, Surveys and Questionnaires, hemic and lymphatic diseases, Medicine, Tomography, TOR Serine-Threonine Kinases, Immunosuppression, General Medicine, Viral Load, pre-emptive treatment, X-Ray Computed, 3. Good health, Cross-Sectional Studies, Humans, Immunosuppressive Agents, Lymphoproliferative Disorders, Positron-Emission Tomography, Rituximab, Tomography, X-Ray Computed, Viremia, Organ Transplantation, Transplant Recipients, post-transplant lymphoproliferative disease, Viral load, medicine.drug, medicine.medical_specialty, survey, Internal medicine, business.industry, Immunology, 3111 Biomedicine, business, Solid organ transplantation, Serostatus
Abstract

There is limited clinical evidence on the utility of the monitoring of Epstein–Barr virus (EBV) DNAemia in the pre-emptive management of post-transplant lymphoproliferative disease (PTLD) in solid organ transplant (SOT) recipients. We investigated current preventive measures against EBV-related PTLD through a web-based questionnaire sent to 669 SOT programmes in 35 European countries. This study was performed on behalf of the ESGICH study group from the European Society of Clinical Microbiology and Infectious Diseases. A total of 71 SOT programmes from 15 European countries participated in the study. EBV serostatus of the recipient is routinely obtained in 69/71 centres (97%) and 64 (90%) have access to EBV DNAemia assays. EBV monitoring is routinely used in 85.9% of the programmes and 77.4% reported performing pre-emptive treatment for patients with significant EBV DNAemia levels. Pre-emptive treatment for EBV DNAemia included reduction of immunosuppression in 50.9%, switch to mammalian target of rapamycin inhibitors in 30.9%, and use of rituximab in 14.5% of programmes. Imaging by whole-body 18-fluoro-deoxyglucose positron emission tomography (FDG-PET) is used in 60.9% of centres to rule out PTLD and complemented computer tomography is used in 50%. In 10.9% of centres, FDG-PET is included in the first-line diagnostic workup in patients with high-risk EBV DNAemia. Despite the lack of definitive evidence, EBV load measurements are frequently used in Europe to guide diagnostic workup and pre-emptive reduction of immunosuppression. We need prospective and controlled studies to define the impact of EBV monitoring in reducing the risk of PTLD in SOT recipients.

Published
2015
Full Text
View/download PDF

25. Vascular access

Author

McCullough, K. P., primary, Lok, C. E., additional, Fluck, R. J., additional, Spergel, L. M., additional, Andreucci, V. E., additional, Fort, J., additional, Krishnan, M., additional, Fissell, R. B., additional, Kawanishi, H., additional, Saran, R., additional, Port, F. K., additional, Robinson, B. M., additional, Pisoni, R. L., additional, Shinzato, T., additional, Shionoya, Y., additional, Fukui, H., additional, Sasaki, M., additional, Miwa, M., additional, Toma, S., additional, Lin, C.-C., additional, Yang, W.-C., additional, Simone, S., additional, Loverre, A., additional, Cariello, M., additional, Divella, C., additional, Castellano, G., additional, Gesualdo, L., additional, Grandaliano, G., additional, Pertosa, G., additional, Mattei, S., additional, Pignatelli, G., additional, Corradini, M., additional, Stefani, A., additional, Bovino, A., additional, Iannuzzella, F., additional, Vaglio, A., additional, Manari, A., additional, Pasquali, S., additional, Chan, J.-S., additional, Wu, T.-C., additional, Roy-Chaudhury, P., additional, Shih, C.-C., additional, Chen, J.-W., additional, Ponce, P., additional, Scholz, C., additional, Goncalves, P., additional, Grassmann, A., additional, Canaud, B., additional, Marcelli, D., additional, Suzuki, S., additional, Shibata, K., additional, Kuji, T., additional, Kawata, S., additional, Koguchi, N., additional, Nishihara, M., additional, Satta, H., additional, Toya, Y., additional, Umemura, S., additional, Corbett, R., additional, Demicheli, N., additional, Iori, F., additional, Grechy, L., additional, Khiroya, R., additional, Ellis, D., additional, Crane, J., additional, Hamady, M., additional, Gedroyc, W., additional, Duncan, N., additional, Vincent, P., additional, Caro, C., additional, Sarween, N., additional, Price, A., additional, Powers, S., additional, Allen, C., additional, Holland, M., additional, Gupta, I., additional, Baharani, J., additional, Parisotto, M. T., additional, Schoder, V., additional, Kaufmann, P., additional, Miriunis, C., additional, Moura, A., additional, Madureira, J., additional, Alija, P., additional, Fernandes, J., additional, Oliveira, J. G., additional, Lopez, M., additional, Felgueiras, M., additional, Amado, L., additional, Sameiro-Faria, M., additional, Miranda, V., additional, Vieira, M., additional, Santos-Silva, A., additional, Costa, E., additional, David, P., additional, Capurro, F., additional, Brustia, M., additional, De Mauri, A., additional, Ruva, C., additional, Chiarinotti, D., additional, Gravellone, L., additional, De Leo, M., additional, Turkvatan, A., additional, Kirkpantur, A., additional, Mandiroglu, S., additional, Afsar, B., additional, Seloglu, B., additional, Alkis, M., additional, Erkula, S., additional, GURBUZ, H. G., additional, Serin, M., additional, CALIK, Y., additional, Mandiroglu, F., additional, Balci, M., additional, Rikker, C., additional, Juhasz, E., additional, Tornoci, L., additional, Tovarosi, S., additional, Greguschik, J., additional, Rosivall, L., additional, Ibeas, J., additional, Valeriano, J., additional, Vallespin, J., additional, Fortuno, J., additional, Rodriguez-Jornet, A., additional, Cabre, C., additional, Merino, J., additional, Vinuesa, X., additional, Bolos, M., additional, Branera, J., additional, Mateos, A., additional, Jimeno, V., additional, Grau, C., additional, Criado, E., additional, Moya, C., additional, Ramirez, J., additional, Gimenez, A., additional, Garcia, M., additional, Kirmizis, D., additional, Kougioumtzidou, O., additional, Vakianis, P., additional, Bandera, A., additional, Veniero, P., additional, Brunori, G., additional, Dimitrijevic, Z., additional, Cvetkovic, T., additional, Paunovic, K., additional, Stojanovic, M., additional, Ljubenovic, S., additional, Mitic, B., additional, Djordjevic, V., additional, Aicha Henriette, S., additional, Farideh, A., additional, Daniela, B., additional, Zafer, T., additional, Francois, C., additional, Donati, G., additional, Scrivo, A., additional, Cianciolo, G., additional, La Manna, G., additional, Panicali, L., additional, Rucci, P., additional, Marchetti, A., additional, Giampalma, E., additional, Galaverni, M., additional, Golfieri, R., additional, Stefoni, S., additional, Skornyakov, I., additional, Kiselev, N., additional, Rozhdestvenskaya, A., additional, Stolyar, A., additional, Ancarani, P. P. A., additional, Devoto, E., additional, Dardano, G. G. D., additional, Coskun yavuz, Y., additional, Selcuk, N. Y., additional, Guney, I., additional, Altintepe, L., additional, Gerasimovska, V., additional, Gerasimovska-Kitanovska, B., additional, Persic, V., additional, Buturovic-Ponikvar, J., additional, Arnol, M., additional, Ponikvar, R., additional, Conti, N., additional, Scrivano, J., additional, Pettorini, L., additional, Giuliani, A., additional, Punzo, G., additional, Mene, P., additional, Pirozzi, N., additional, Kocyigit, I., additional, Unal, A., additional, Guney, A., additional, Mavili, E., additional, Deniz, K., additional, Sipahioglu, M., additional, Eroglu, E., additional, Tokgoz, B., additional, Oymak, O., additional, Gunal, A., additional, Boubaker, K., additional, Kaaroud, H., additional, Kheder, A., additional, Vidal, M., additional, Amengual, M. J., additional, Orellana, R., additional, Sanfeliu, I., additional, Marquina, D., additional, Xirinachs, M., additional, Sanchez, E., additional, Rey, M., additional, Strozecki, P., additional, Flisinski, M., additional, Kapala, A., additional, Manitius, J., additional, Gerasimovska-Kitanovska, B. D., additional, Sikole, A., additional, Weber, E., additional, Adrych, D., additional, Wolyniec, W., additional, Liberek, T., additional, Rutkowski, B., additional, Oguchi, K., additional, Nakahara, T., additional, Okamoto, M., additional, Iwabuchi, H., additional, Asano, M., additional, Rap, O., additional, Ruiz-Valverde, M., additional, Rodriguez-Murillo, J. A., additional, Mallafre-Anduig, J. M., additional, Zeid, M. M., additional, Deghady, A. A., additional, Elshair, H. S., additional, Elkholy, N. A., additional, Panagoutsos, S., additional, Devetzis, V., additional, Roumeliotis, A., additional, Kantartzi, K., additional, Mourvati, E., additional, Vargemezis, V., additional, Passadakis, P., additional, Kang, S. H., additional, Jung, S. Y., additional, Lee, S. H., additional, Cho, K. H., additional, Park, J. W., additional, Yoon, K. W., additional, and Do, J. Y., additional

Published
2013
Full Text
View/download PDF

33. Reply

Author

Skofic, N., primary, Arnol, M., additional, Buturovic-Ponikvar, J., additional, and Ponikvar, R., additional

Published
2012
Full Text
View/download PDF

50. COVID-19 Pandemic Waves and Mortality Among Patients on Kidney Replacement Therapy

Author

Priya Vart, Kitty J. Jager, Miha Arnol, Raphaël Duivenvoorden, Casper F.M. Franssen, Marc Groeneveld, Marc H. Hemmelder, Fanny Lepeytre, Thomas Malfait, Karsten Midtvedt, Sandip Mitra, Carme Facundo, Marlies Noordzij, Carlos C. Reina, Seda Safak, Nestor Toapanta, Luuk B. Hilbrands, Ron T. Gansevoort, Institut Català de la Salut, [Vart P] Department of Internal Medicine, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. Department of Clinical Pharmacy & Pharmacology, University Medical Center Groningen, Groningen, The Netherlands. [Jager KJ] ERA Registry, Department of Medical Informatics, Amsterdam University Medical Center, Amsterdam Public Health Research Institute, Amsterdam, The Netherlands. [Arnol M] Department of Nephrology, University Medical Center Ljubljana, Medical Faculty, University of Ljubljana, Ljubljana, Slovenia. [Duivenvoorden R] Department of Nephrology, Radboud University Medical Center, Nijmegen, The Netherlands. [Franssen CFM] Department of Internal Medicine, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. [Groeneveld M] Haaglanden Medical Center, the Hague, The Netherlands. [Toapanta N] Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus, Groningen Kidney Center (GKC), Cardiovascular Centre (CVC), Medical Informatics, APH - Aging & Later Life, APH - Quality of Care, APH - Global Health, ACS - Pulmonary hypertension & thrombosis, Interne Geneeskunde, MUMC+: MA Nefrologie (9), and RS: Carim - V02 Hypertension and target organ damage

Subjects
kidney, Otros calificadores::Otros calificadores::Otros calificadores::/mortalidad [Otros calificadores], terapéutica::tratamiento de reemplazo renal::diálisis renal [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], COVID-19, Ronyons - Trasplantació - Mortalitat, Diàlisi, pandemic wave, Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES], terapéutica::tratamiento de reemplazo renal::trasplante de riñón [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], mortality, COVID-19 (Malaltia), Renal disorders Radboud Institute for Molecular Life Sciences [Radboudumc 11], Nephrology, Other subheadings::Other subheadings::Other subheadings::/mortality [Other subheadings], Therapeutics::Renal Replacement Therapy::Kidney Transplantation [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES], dialysis, transplant, Renal disorders Radboud Institute for Health Sciences [Radboudumc 11], Therapeutics::Renal Replacement Therapy::Renal Dialysis [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT]
Abstract

COVID-19; Dialysis; Mortality COVID-19; Diálisis: Mortalidad COVID-19; Diàlisi; Mortalitat This work was supported with unrestricted grants from European Renal Association (ERA), Nierstichting (Dutch Kidney Foundation), Baxter, and Sandoz unrestricted research grants.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results